FTC pushes against AbbVie's efforts to dismiss monopolization claims in AndroGel case
MLex Summary: The US Federal Trade Commission has opposed AbbVie and Besins Healthcare's motion for summary judgment against monopolization claims regarding AndroGel. The FTC says that the issues should go to...To view the full article, register now.
Already a subscriber? Click here to view full article